Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. SASLT guidelines: Update in treatment of Hepatitis C virus infection.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2016
   Guideline
2. Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy.Open forum infectious diseases · 2020
   Article
3. Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct-acting antiviral agents.Immunology and cell biology · 2018
   Article
4. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.Immunological reviews · 2018
   Review
5. Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.Therapeutic advances in gastroenterology · 2017
   Article
6. Resurrection of response-guided therapy for sofosbuvir combination therapies.Journal of hepatology · 2016
   Article
7. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.World journal of hepatology · 2016
   Article
8. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.Journal of hepatology · 2016
   Article
9. Reply to Harrington et al.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015
   Article

Corrections and comments

• Commented on by
  Reply to Harrington et al.2015
• Comment on
  Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.2015

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as